All together, these studies demonstrate that bispecific antibodies that target CHI3L1 and CTLA-4 have impressive antitumor effects while inducing CD8+ cytotoxic T cell differentiation and tumor cytotoxicity. This evidence concerns the gene CHI3L1 and neoplasm.